Vulvovaginal Candidiasis
📧 Sign up to get email alerts when something new happens for Vulvovaginal Candidiasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS safety_alert · 2024-07-17Clinical Trial Update: Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
This clinical trial update discusses safety data collection for pregnant subjects exposed to ibrefungerp and potential infant outcomes. The …
-
CLINICAL_TRIALS trial_result · 2024-07-10Clinical Trial Update: Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis [Phase 3]
Phase 3 trial results for ibrefungERp (Brexafemme) in the treatment of complicated vulvovaginal candidiasis have been completed, with result…
-
FDA approval · 2024-06-25FDA Approved: FLUCONAZOLE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for Fluconazole from Dr. Reddy's Laboratories Limited (ANDA 076658).
-
CLINICAL_TRIALS research · 2024-06-12Clinical Trial Update: Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection [Phase 1, Phase 2]
This update describes a Phase 1/2 clinical trial evaluating the efficacy, safety, and dose response of a live biotherapeutic product for acu…
-
CLINICAL_TRIALS research · 2024-05-28Clinical Trial Update: DeVEnIR: Defining Vulvovaginal Candidiasis - Elements of Infection and Remedy
A clinical trial update describing the DeVEnIR study, which aims to define infection elements and remedies for vulvovaginal candidiasis, and…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-05-16Clinical Trial Update: Comparative Performance of a Vaginal Yeast Test
The document summarizes an ongoing clinical trial assessing the comparative performance of a vaginal yeast diagnostic test for vulvovaginal …
-
CLINICAL_TRIALS trial_result · 2024-05-13Clinical Trial Update: Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis [Phase 3]
Phase 3 clinical trial evaluated the efficacy and safety of natamycin and lactulose vaginal suppositories for vulvovaginal candidiasis; the …
-
CLINICAL_TRIALS trial_result · 2024-05-02Clinical Trial Update: Blue Light Emitting Diode Therapy on Vulvovaginal Candidiasis [NA]
A completed Cairo University trial investigates blue light emitting diode therapy for vulvovaginal candidiasis, including recurrent cases.
-
FDA approval · 2024-04-11FDA Approved: VIVJOA — Supplemental Application (Mycovia Pharmaceuticals, Inc.)
The FDA approved a supplemental application for VIVJOA (oteseconazole) submitted by Mycovia Pharmaceuticals, Inc.
-
FDA approval · 2024-02-29FDA Approved: CLOTRIMAZOLE — Original Application (Rising Pharma Holdings, Inc.)
The FDA approved the original application for clotrimazole from Rising Pharma Holdings, enabling a generic version of this antifungal. It co…
-
FDA approval · 2023-11-17FDA Approved: MONISTAT 3 COMBINATION PACK 3 OVULE INSERTS — Supplemental Application (Insight Pharmaceuticals LLC)
The FDA approved a supplemental application for MONISTAT 3 Combination Pack 3 Ovule Inserts (miconazole nitrate) for the treatment of vulvov…
-
FDA approval · 2023-10-24FDA Approved: FLUCONAZOLE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approves a supplemental application for fluconazole submitted by Dr. Reddy's Laboratories Limited.
-
FDA approval · 2023-07-14FDA Approved: FLUCONAZOLE — Supplemental Application (Baxter Healthcare Company)
FDA approved Baxter Healthcare Company's supplemental application for fluconazole (ANDA076766). This action confirms authorization of a gene…
-
CLINICAL_TRIALS trial_result · 2023-06-18Clinical Trial Update: Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) [Phase 3]
A Phase 3 study evaluating oral ibrexafungerp (SCY-078) versus placebo in recurrent vulvovaginal candidiasis has completed with results post…
-
CLINICAL_TRIALS trial_result · 2023-05-17Clinical Trial Update: The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms [Phase 3]
Phase 3 clinical trial investigating a medical grade honey formulation (L-Mesitran) for symptoms of recurrent vulvovaginal candidiasis.
-
FDA approval · 2023-03-17FDA Approved: FLUCONAZOLE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for fluconazole submitted by Rising Pharma Holdings, Inc., indicating approval of a generic formulat…
-
CLINICAL_TRIALS trial_result · 2022-09-22Clinical Trial Update: A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC) [Phase 2, Phase 3]
Phase IIb/III study update for Prof-001 in recurrent vulvovaginal candidiasis is ongoing with phases 2 and 3 indicated; current status is un…
-
CLINICAL_TRIALS trial_result · 2022-05-20Clinical Trial Update: A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis [Phase 2]
Phase 2 clinical trial investigating chlorhexidine as a treatment for vulvovaginal candidiasis.
-
FDA approval · 2022-04-26FDA Approved: VIVJOA — Original Application (Mycovia Pharmaceuticals, Inc.)
FDA approved Vivjoa (oteseconazole) from Mycovia Pharmaceuticals for the treatment of recurrent vulvovaginal candidiasis, marking the first …
-
CLINICAL_TRIALS trial_result · 2022-03-14Clinical Trial Update: Study Evaluating the Efficacy and Safety of Miconazole Nitrate + Domiphen Bromide Vaginal Cream in the Treatment of Subjects With Acute Vulvovaginal Candidiasis [Phase 2]
Phase 2 trial evaluating the efficacy and safety of miconazole nitrate plus domiphen bromide vaginal cream for acute vulvovaginal candidiasi…
-
CLINICAL_TRIALS trial_result · 2022-02-04Clinical Trial Update: Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections [Phase 3]
Phase 3 study of oral oteseconazole for recurrent vulvovaginal candidiasis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-01-13Clinical Trial Update: A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) [Phase 3]
Phase 3 trial update for oteseconazole in recurrent vulvovaginal candidiasis; the study completed and results were posted in January 2022.
-
CLINICAL_TRIALS trial_result · 2021-12-20Clinical Trial Update: A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) [Phase 3]
Phase 3 study evaluating oteseconazole (VT-1161) for recurrent vulvovaginal candidiasis has completed, with results posted in December 2021.
-
FDA approval · 2021-10-25FDA Approved: DIFLUCAN — Supplemental Application (Roerig)
The FDA approved a supplemental application for Diflucan (fluconazole) submitted by Roerig.
-
CLINICAL_TRIALS trial_result · 2021-10-12Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis [Phase 3]
Phase 3 trial comparing SHR8008 to fluconazole for recurrent vulvovaginal candidiasis to evaluate efficacy and safety.